RVNC - Revance Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Revance Therapeutics, Inc.

7555 Gateway Boulevard
Newark, CA 94560
United States
510-742-3400
http://www.revance.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees170

Key Executives

NameTitlePayExercisedYear Born
Mr. L. Daniel BrowneCo-Founder, Pres, CEO & Director984.4k575k1962
Mr. Tobin C. SchilkeCFO & Principal Accounting Officer89.88kN/A1975
Dr. Abhay JoshiChief Operating Officer710.46k19.21k1963
Ms. Caryn Gordon McDowellSr. VP, Gen. Counsel & Corp. Sec.537.47kN/A1970
Ms. Jeanie D. HerbertSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. It is also developing DAXI for forehead lines and lateral canthal lines; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. Revance Therapeutics, Inc. has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.

Corporate Governance

Revance Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.